insulin degludec vs insulin glargine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin degludec · Tresiba

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT00982644 · Phase 3 · completed

The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)

Result source: NCT00982644

insulin glargine · Lantus

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00069784 · Phase 3 · completed

The trial randomized 12,537 participants and used adjudicated clinical cardiovascular events, but treatment assignment was open-label rather than double-blinded. Neither primary cardiovascular endpoint was statistically significant in favor of insulin glargine, so the evidence supports a well-powered but inconclusive or negative finding rather than strong evidence of benefit.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin degludecinsulin glargine
HbA1c, change-1.4% vs -1.6%vs Insulin Icodecwk 26 · n 294NCT04795531
22 other results
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.1% vs -1.2% once daily · wk 52 · n 773 · Phase 3 · primary NCT00982644
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
-0.6% vs -0.8%vs Insulin Icodecwk 26 · n 201NCT06340854
18 other results
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.7% vs -1.4% wk 26 · n 134 · Phase 4 · primary NCT00391027
  • -2.0% vs -1.8% wk 26 · n 154 · Phase 4 · primary NCT00418522
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -1.3% vs -1.4% wk 24 · n 30 · Phase 4 · primary NCT00686712
  • -1.9% vs -1.4% wk 24 · n 25 · Phase 4 · primary NCT00686712
  • -1.3% vs -1.4% wk 12 · n 46 · Phase 4 · primary NCT02455076
  • -1.1% vs -1.4% wk 12 · n 50 · Phase 4 · primary NCT02455076
  • -1.9% vs -1.7% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -1.7% vs -1.5% wk 18 · n 134 · Phase 4 · secondary NCT00391027
  • -1.6% vs -1.3% wk 12 · n 134 · Phase 4 · secondary NCT00391027
  • -1.3% vs -1.1% wk 8 · n 134 · Phase 4 · secondary NCT00391027
  • -0.8% vs -0.6% wk 4 · n 134 · Phase 4 · secondary NCT00391027
  • -0.4% vs -0.3% wk 2 · n 134 · Phase 4 · secondary NCT00391027
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
Body weight, change (kg)2.3 vs 2.8vs Insulin Icodecwk 26 · n 294NCT04795531
15 other results
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs -1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
0.6 vs 2.0vs Insulin Icodecwk 26 · n 202NCT06340854
7 other results
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • 2.2 vs 1.1 wk 26 · n 125 · Phase 4 · secondary NCT00391027
  • 3.5 vs 2.3 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • 0.5 vs 0.2 wk 24 · n 48 · Phase 4 · secondary NCT00360698
  • -1 vs -0.5 n 42 · Phase 4 · secondary NCT02455076
HbA1c below 7%75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT0167611648.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
4 other results
  • 22.4% vs 8.8% wk 24 · n 49 · Phase 4 · primary NCT00360698
  • 62.6% vs 47.6% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
Fasting plasma glucose, change-3.0 vs -3.0vs Insulin Icodecwk 26 · n 290NCT04795531
15 other results
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
-3.6 vs -2.1vs Liraglutidewk 24 · n 468NCT01117350
4 other results
  • -1.7 vs -3.3 wk 26 · n 134 · Phase 4 · secondary NCT00391027
  • -2.9 vs -3.0 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.8 vs -0.8 wk 10 · n 154 · Phase 4 · secondary NCT01226043
3-point MACE (% with event)—Not posted · NCT05802862—Not posted · NCT00044447

HbA1c, change

insulin degludec
-1.4% vs -1.6%vs Insulin Icodecwk 26 · n 294NCT04795531
22 other results
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.1% vs -1.2% once daily · wk 52 · n 773 · Phase 3 · primary NCT00982644
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
insulin glargine
-0.6% vs -0.8%vs Insulin Icodecwk 26 · n 201NCT06340854
18 other results
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.7% vs -1.4% wk 26 · n 134 · Phase 4 · primary NCT00391027
  • -2.0% vs -1.8% wk 26 · n 154 · Phase 4 · primary NCT00418522
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -1.3% vs -1.4% wk 24 · n 30 · Phase 4 · primary NCT00686712
  • -1.9% vs -1.4% wk 24 · n 25 · Phase 4 · primary NCT00686712
  • -1.3% vs -1.4% wk 12 · n 46 · Phase 4 · primary NCT02455076
  • -1.1% vs -1.4% wk 12 · n 50 · Phase 4 · primary NCT02455076
  • -1.9% vs -1.7% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -1.7% vs -1.5% wk 18 · n 134 · Phase 4 · secondary NCT00391027
  • -1.6% vs -1.3% wk 12 · n 134 · Phase 4 · secondary NCT00391027
  • -1.3% vs -1.1% wk 8 · n 134 · Phase 4 · secondary NCT00391027
  • -0.8% vs -0.6% wk 4 · n 134 · Phase 4 · secondary NCT00391027
  • -0.4% vs -0.3% wk 2 · n 134 · Phase 4 · secondary NCT00391027
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085

Body weight, change (kg)

insulin degludec
2.3 vs 2.8vs Insulin Icodecwk 26 · n 294NCT04795531
15 other results
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs -1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
insulin glargine
0.6 vs 2.0vs Insulin Icodecwk 26 · n 202NCT06340854
7 other results
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • 2.2 vs 1.1 wk 26 · n 125 · Phase 4 · secondary NCT00391027
  • 3.5 vs 2.3 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • 0.5 vs 0.2 wk 24 · n 48 · Phase 4 · secondary NCT00360698
  • -1 vs -0.5 n 42 · Phase 4 · secondary NCT02455076

HbA1c below 7%

insulin degludec
75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116
insulin glargine
48.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
4 other results
  • 22.4% vs 8.8% wk 24 · n 49 · Phase 4 · primary NCT00360698
  • 62.6% vs 47.6% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085

Fasting plasma glucose, change

insulin degludec
-3.0 vs -3.0vs Insulin Icodecwk 26 · n 290NCT04795531
15 other results
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
insulin glargine
-3.6 vs -2.1vs Liraglutidewk 24 · n 468NCT01117350
4 other results
  • -1.7 vs -3.3 wk 26 · n 134 · Phase 4 · secondary NCT00391027
  • -2.9 vs -3.0 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.8 vs -0.8 wk 10 · n 154 · Phase 4 · secondary NCT01226043

3-point MACE (% with event)

insulin degludec
—Not posted · NCT05802862
insulin glargine
—Not posted · NCT00044447
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. insulin degludec: 11 of 11 rows · insulin glargine: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin degludec
Rows use multiple source trials
insulin glargine
Rows use multiple source trials
BMI
absolute change · kg
0.43 vs 0.4 NovoRapid kg @ 16wka,b,c,d
NCT03268005 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.7 Insulin Only kga,b,c,d
NCT02455076 · Phase 4 · registry result, not featured evidence
2 other source trials
0.7 vs 0.4 Insulin Glargine (Lantus®) kg @ 26wk
NCT00391027 · Phase 4 · registry result, not featured evidence
1.22 vs 0.8 Insulin Glargine kg @ 26wk
NCT00418522 · Phase 4 · registry result, not featured evidence
HbA1c
absolute value · percentage points
8.2% (n=72) vs 7.4% (n=59) Glargine @ 12wkb,c,e
NCT03336528 · Phase 4 · registry result, not featured evidence
7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wkb,c,e
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=200) @ 32wkf,b,c,g
NCT02298192 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.01% (n=189) @ 32wk
NCT02298192 · Phase 3 · registry result, not featured evidence
-1.19% (n=355) @ 52wkf,b,c,g
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
show 3 more doses
-1.19% (n=355) @ 52wk
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.16% (n=360) @ 52wk
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.16% (n=360) @ 52wk
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
HbA1c Less Than 6.5%
event count · % of participants
49.4% (n=271) vs 62.6% (n=273) Liraglutide @ 52wk*f,h,a,b,c,i
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 134 Participants as posted
show 1 more dose
77.5% (n=275) vs 62.6% (n=273) Liraglutide @ 52wk*
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 213 Participants as posted
27.6% (n=134) vs 19% (n=121) Insulin Glargine (Lantus®) @ 26wk*h,a,b,c,i
NCT00391027 · Phase 4 · registry result, not featured evidence · converted to % from 37 participants as posted
HbA1c Less Than 7 Without Hypoglycemia
event count · % of participants
44% (n=348) vs 27.7% (n=173) BIAsp 30 @ 26wk*BIDh,a,b,c,j
Yes
NCT02762578 · Phase 3 · registry result, not featured evidence · converted to % from 153 Participants as posted
26.2% (n=42) vs 18.6% (n=43) Insulin Only @ 12wk*h,a,b,c,j
NCT02455076 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
HbA1c Less Than 7 Without Weight Gain
event count · % of participants
8.1% (n=271) vs 52% (n=273) Liraglutide @ 52wk*f,h,a,b,c,k
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
show 1 more dose
16% (n=275) vs 52% (n=273) Liraglutide @ 52wk*
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 44 Participants as posted
19% (n=42) vs 11.6% (n=43) Insulin Only @ 12wk*h,a,b,c,k
NCT02455076 · Phase 4 · registry result, not featured evidence · converted to % from 8 Participants as posted
HbA1c Less Than 7%
event count · % of participants
49.7% (n=167) vs 53% (n=151) Liraglutide @ 26wk*f,h,a,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
show 1 more dose
79.8% (n=341) vs 53% (n=151) Liraglutide @ 26wk*
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 272 Participants as posted
62.7% (n=134) vs 55.4% (n=121) Insulin Glargine (Lantus®) @ 26wk*h,a,b,c
NCT00391027 · Phase 4 · registry result, not featured evidence · converted to % from 84 participants as posted
Dropout rate
21.5%once dailyl
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
2%
NCT01959529 · Phase 3
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
2.7%
NCT04795531 · Phase 3 · registry result, not featured evidence
6.7%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
8.5%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
19.3%l
NCT00069784 · Phase 3
show 29 more results
11.3%
NCT05114590 · Phase 4 · registry result, not featured evidence
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
1.3%
NCT02561130 · Phase 4 · registry result, not featured evidence
8.5%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
—Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
2%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
8.6%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
15.2%
NCT00751114 · Phase 4 · registry result, not featured evidence
12.3%0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
0%0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
23.5%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
33.3%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
44%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
18.5%
NCT00391027 · Phase 4 · registry result, not featured evidence
37.9%
NCT00418522 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
1.5%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
9.3%Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
Discontinued due to AEs
2.6%once dailyl
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
0%
NCT01959529 · Phase 3
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
—
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
—
NCT04795531 · Phase 3 · registry result, not featured evidence
0.6%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
—
NCT03268005 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
2.2%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
0.3%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
1.7%l
NCT00069784 · Phase 3
show 29 more results
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
—
NCT04153981 · Phase 4 · registry result, not featured evidence
—
NCT02561130 · Phase 4 · registry result, not featured evidence
6.4%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
—Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
0%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
1.2%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
0.8%
NCT00751114 · Phase 4 · registry result, not featured evidence
—0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
—0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
2.6%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
3.3%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
4%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT00391027 · Phase 4 · registry result, not featured evidence
3.2%
NCT00418522 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
—
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
Serious AEs
15.1%once dailyl
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
38.6%
NCT01959529 · Phase 3
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
3.7%
NCT03336528 · Phase 4 · registry result, not featured evidence
6.7%
NCT04588259 · Phase 3 · registry result, not featured evidence
5.1%
NCT04795531 · Phase 3 · registry result, not featured evidence
4%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
20.8%
NCT03078478 · Phase 3 · registry result, not featured evidence
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.8%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
—Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
3.1%Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT01570751 · Phase 3 · registry result, not featured evidence
4.9%l
NCT00069784 · Phase 3
show 29 more results
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
14.9%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
22.9%Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
23.5%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
2.3%Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
3.1%Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
1%Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
10.1%Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
0.6%Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
6.3%
NCT00751114 · Phase 4 · registry result, not featured evidence
0%0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
0%0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
11.9%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
0%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
4%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT00391027 · Phase 4 · registry result, not featured evidence
—
NCT00418522 · Phase 4 · registry result, not featured evidence
0%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
5.8%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.3%Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
Most frequent reported AEs
once dailyl
nasopharyngitis 23.9%
headache 13.8%
diarrhoea 10.8%
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 23 more results
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
emergency room visit for bilateral knee pain 1.2%
emergency room visit for congestive heart failure 1.2%
emergency room visit for wound infection 1.2%
NCT03336528 · Phase 4 · registry result, not featured evidence
diabetic retinopathy 14.7%
hyperlipidaemia 14%
upper respiratory tract infection 9.3%
NCT04588259 · Phase 3 · registry result, not featured evidence
covid-19 4.8%
influenza 3.1%
diabetic retinopathy 2%
NCT04795531 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.7%
nasopharyngitis 5.1%
diabetic retinopathy 3.4%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
nasopharyngitis 19%
upper respiratory tract infection 18.1%
diarrhoea 9%
NCT03078478 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 33.6%
weight increased 7%
pharyngitis 5.5%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
lipase increased 10%
headache 9.3%
nasopharyngitis 8.9%
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 1.4%
NCT01570751 · Phase 3 · registry result, not featured evidence
l
hypoglycaemia 5.7%
upper respiratory tract infection 5.7%
NCT05114590 · Phase 4 · registry result, not featured evidence
show 22 more results
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
genitourinary infection 5.2%
abdominal pain 3.9%
injury 3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
nausea 10.6%
vomiting 2.1%
NCT02455076 · Phase 4 · registry result, not featured evidence
nausea 41.7%
vomiting 22.9%
NCT02455076 · Phase 4 · registry result, not featured evidence
nausea 9.8%
vomiting 5.9%
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.9%
headache 5%
diarrhoea 3.7%
NCT01117350 · Phase 4 · registry result, not featured evidence
nasopharyngitis 7.5%
diarrhoea 3.1%
headache 1.3%
NCT01117350 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 1.8%
nasopharyngitis 1.3%
sinusitis 1%
NCT01226043 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.8%
sinusitis 7.5%
oedema peripheral 5%
NCT01226043 · Phase 4 · registry result, not featured evidence
nasopharyngitis 3.6%
upper respiratory tract infection 2.4%
sinusitis 1.2%
NCT01226043 · Phase 4 · registry result, not featured evidence
headache 6.3%
influenza 3.4%
nasopharyngitis 3.4%
NCT00751114 · Phase 4 · registry result, not featured evidence
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
symptomatic hypoglycemia 76.7%
asymptomatic retinal hemorrhage 3.3%
urinary tract infection 0%
NCT00686712 · Phase 4 · registry result, not featured evidence
symptomatic hypoglycemia 96%
asymptomatic retinal hemorrhage 0%
urinary tract infection 0%
NCT00686712 · Phase 4 · registry result, not featured evidence
hypoglycaemia 70.4%
nasopharyngitis 13.3%
cough 6.7%
NCT00391027 · Phase 4 · registry result, not featured evidence
hypoglycaemia 67.9%
tremor 31.6%
dizziness 18.9%
NCT00418522 · Phase 4 · registry result, not featured evidence
nausea 11.1%
diarrhoea 5.6%
hypertension 5.6%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.8%
diabetic retinopathy 7.3%
diarrhoea 1.9%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
drug titration error 9.8%
urinary tract infection 6.3%
influenza 5.8%
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eAssessment timepoints differ: 24 weeks versus 12 weeks.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gAssessment timepoints differ: 52 weeks versus 32 weeks.
  8. hThe reported result categories differ.
  9. iAssessment timepoints differ: 26 weeks versus 52 weeks.
  10. jAssessment timepoints differ: 12 weeks versus 26 weeks.
  11. kAssessment timepoints differ: 12 weeks versus 52 weeks.
  12. lPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin degludec

Time to First MACE 8.5% (n=3818) vs 9.3% (n=3819) Insulin Glargine
event count · % of participants
First EAC-confirmed MACE
NCT01959529 · Phase 3 · converted to % from 325 Participants as posted
Non-fatal MI 3.7% (n=3818) vs 4.3% (n=3819) Insulin Glargine
event count · % of participants
Myocardial infarction (non-fatal)
NCT01959529 · Phase 3 · converted to % from 143 Participants as posted
Stroke 1.8% (n=3818) vs 1.9% (n=3819) Insulin Glargine
responder rate · % of participants
Stroke (non-fatal)
NCT01959529 · Phase 3 · converted to % from 68 Participants as posted
CV Death 3% (n=3818) vs 3.1% (n=3819) Insulin Glargine
responder rate · % of participants
Cardiovascular death
NCT01959529 · Phase 3 · converted to % from 114 Participants as posted
Hypoglycemia Episodes Level 3 280 vs 472 Insulin Glargine count
event count · count
NCT01959529 · Phase 3
show 2 more results
2 vs 0 Insulin Icodec count @ 31wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0 vs 0 Insulin Icodec count @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
Hypoglycemia Event Incidence 4.9% (n=3818) vs 6.6% (n=3819) Insulin Glargine
event rate · % of participants
NCT01959529 · Phase 3 · converted to % from 187 Participants as posted
HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Daily Glucose mg/dL 9.98 vs 10.03 Glargine mmol/L @ 1wk
absolute value · mmol/L
Day 1 up to Day 10
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 179.75 mg/dL as posted
Daily Glucose mg/dL 8.71 vs 7.94 Glargine mmol/L @ 4wk
absolute value · mmol/L
Day after discharge up to the 4 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 157 mg/dL as posted
Daily Glucose mg/dL 8.25 vs 7.43 Glargine mmol/L @ 12wk
absolute value · mmol/L
4 week post-discharge up to the 12 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 148.7 mg/dL as posted
Clinically Significant Hypoglycemia Event Incidence 3.7% (n=82) vs 1.3% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
Severe Hypoglycemia Event Incidence 0% (n=82) vs 0% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted

+ 100 further endpoints in the CSV export.

insulin glargine

MACE 3-point Composite 16.6% (n=6264) vs 16.1% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1041 participants as posted
Time to CV Death 7.7% (n=6264) vs 7.6% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: CV death
NCT00069784 · Phase 3 · converted to % from 484 participants as posted
Myocardial Infarction 4.7% (n=6264) vs 4.5% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: nonfatal MI
NCT00069784 · Phase 3 · converted to % from 297 participants as posted
show 1 more result
4.1% (n=6264) vs 3.8% (n=6273) Standard Care*
Endpoint's composition: nonfatal MI
NCT00069784 · Phase 3 · converted to % from 257 participants as posted
MACE Broad 28.6% (n=6264) vs 27.5% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1792 participants as posted
Coronary Revascularization 12.2% (n=6264) vs 11.4% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: revascularization
NCT00069784 · Phase 3 · converted to % from 763 participants as posted
Microvascular Composite 21.1% (n=6264) vs 21.7% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1323 participants as posted
Albuminuria Progression 18.4% (n=6264) vs 18.7% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: albuminuria progression
NCT00069784 · Phase 3 · converted to % from 1153 participants as posted
Type 2 Diabetes Incidence 24.7% (n=737) vs 31.2% (n=719) Standard Care
event rate · % of participants
NCT00069784 · Phase 3
Time in Range 24 h 26.22 % of time @ 16wk
absolute change · % of time
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Glucose Variability CV 5% (n=113) @ 16wk
absolute change · percentage points
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Daily Plasma Glucose Change mg/dL -2.91 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -52.48 mg/dL as posted
PMG Change mg/dL -73.66 mg/dL @ 16wk
absolute change · mg/dL
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence

+ 55 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · insulin glargine's landscape